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Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers due to its
aggressive and metastatic nature. PDA is characterized by a rich tumor stroma with
abundant macrophages, fibroblasts, and collagen deposition that can represent up to
90% of the tumor mass. Activation of the tyrosine kinase receptor AXL and expression
of its ligand growth arrest-specific protein 6 (Gas6) correlate with a poor prognosis and
increased metastasis in pancreatic cancer patients. Gas6 is a multifunctional protein that
can be secreted by several cell types and regulates multiple processes, including cancer
cell plasticity, angiogenesis, and immune cell functions. However, the role of Gas6 in
pancreatic cancer metastasis has not been fully investigated. In these studies we find
that, in pancreatic tumors, Gas6 is mainly produced by tumor associated macrophages
(TAMs) and cancer associated fibroblasts (CAFs) and that pharmacological blockade
of Gas6 signaling partially reverses epithelial-to-mesenchymal transition (EMT) of tumor
cells and supports NK cell activation, thereby inhibiting pancreatic cancer metastasis.
Our data suggest that Gas6 simultaneously acts on both the tumor cells and the NK cells
to support pancreatic cancer metastasis. This study supports the rationale for targeting
Gas6 in pancreatic cancer and use of NK cells as a potential biomarker for response to
anti-Gas6 therapy.
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INTRODUCTION
Growth arrest-specific gene 6 (Gas6) is a multifunctional factor that regulates several processes in
normal physiology and pathophysiology (1). Gas6 binds to the Tyro3, Axl, and Mer (TAM) family
of receptor tyrosine kinases (TAM receptors) with the highest affinity for Axl (2). Gas6 supports
erythropoiesis, platelet aggregation, angiogenesis, efferocytosis and inhibits the immune response
(3). Gas6 is critical for the maintenance of immune homeostasis and mice deficient in Gas6 or
TAM receptors experience severe autoimmune diseases (4). Gas6 and its main receptor Axl are
overexpressed in several cancer types including, breast, ovarian, gastric, glioblastoma, lung, and
pancreatic cancer and their expression correlates with a poor prognosis (5). Axl is ubiquitously
expressed in all tissues (6) but is particularly notable in cancer cells, macrophages, dendritic cells
and natural killer cells for its role in driving immunosuppression and tumor progression (7–9).
Several cancer studies have focused on the role of Gas6-Axl signaling on the tumor cells and
have demonstrated that Axl activation supports tumor cell proliferation, epithelial-mesenchymal
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transition (EMT), drug resistance, migration and metastasis (5).
Factors secreted within the tumor microenvironment are able to
sustain Gas6/Axl signaling. Hypoxia Inducible Factor (HIF) has
been shown to bind to the Axl promoter region and upregulate
its expression on renal cell carcinoma cells (10). Secretion of
IL-10 and M-CSF by tumor cells induces tumor associated
macrophages to secrete Gas6 (11). However, only a few studies
have investigated the role of Gas6-Axl signaling in the immune
response to breast cancer, ovarian cancer and melanoma (7, 9).
In solid tumors such as breast or pancreatic cancer, the tumor
stroma can represent up to 80% of the tumor mass and actively
influences cancer progression, metastasis (12–14) and resistance
to therapies (15–17).
Pancreatic ductal adenocarcinoma (PDA) is one of the most
lethal cancers worldwide and better therapies are urgently needed
(18). Metastasis, therapy resistance, and immunosuppression
are key characteristics of pancreatic tumors (19, 20). The
Gas6–Axl pathway is activated in 70% of pancreatic cancer
patients (21) and is associated with a poor prognosis and
increased frequency of distant metastasis (22). Blocking Gas6-
Axl signaling inhibits cancer progression (23, 24) and several
Axl inhibitors and warfarin (a vitamin K antagonist that blocks
Gas6 signaling) are currently being tested in cancer patients,
including PDA patients. While the cancer cell autonomous
functions of Gas6 are well-documented, the effect of Gas6
signaling in the stroma/immune compartment in pancreatic
cancer has not been fully explored. In these studies, we sought
to understand the effect of Gas6 blockade in both the tumor
and the stroma/immune compartments, in vivo, in pancreatic
cancer. Gaining a better understanding of how blockade of Gas6
signaling affects pancreatic cancer is important because it will
help design and interpret the results of the recently launched
clinical trials that are testing anti-Gas6/TAM receptors therapies
in pancreatic cancer patients (25).
RESULTS
Pharmacological Blockade of Gas6 Inhibits
Spontaneous Pancreatic Cancer
Metastasis
To investigate the effect of Gas6 blockade in pancreatic
cancer growth and metastasis, we used an orthotopic syngeneic
pancreatic cancer model, in which pancreatic cancer cells
derived from the gold standard genetic mouse model of
pancreatic cancer (LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre
mice; KPC model), transduced with a reporter lentivirus
expressing zsGreen/luciferase, were orthotopically implanted
into the pancreas of syngeneic immuno-competent mice.
This model faithfully recapitulates features of the human
disease, and tumors are highly infiltrated by macrophages and
are rich in fibroblasts (16, 26, 27). Importantly, pancreatic
tumors from this mouse model also showed expression and
activation of Axl receptor (Supplementary Figure 1A). These
mice were then treated with isotype control IgG antibody
or an anti-Gas6 neutralizing antibody (Figure 1A). This anti-
Gas6 neutralizing antibody has previously been shown to block
Gas6 signaling through the AXL receptor to a similar extent
as an anti-AXL antibody (28). Thirty days after implantation,
pancreatic tumors, lungs, livers, and mesenteric lymph nodes
were surgically removed and analyzed. As expected, control
treated mice showed high levels of Axl receptor activation in
tumors, whereas the anti-Gas6 treated group showed markedly
reduced levels of Axl receptor activation, confirming that anti-
Gas6 antibody has reached the tumor and has blocked Axl
signaling (Supplementary Figures 1A,B). No differences were
seen in primary pancreatic tumor growth (Figure 1B) between
the control and anti-Gas6 treatment groups. However, mice
treated with the anti-Gas6 antibody showed reduced metastasis
to lungs, livers, and mesenteric lymph nodes, compared to
control treated mice, as assessed by biolumiscence ex-vivo
imaging of these organs (Supplementary Figures 1C,D). Since
lungs showed the highest level of metastasis in this model,
lung tissues were further assessed for metastasis by H&E and
cytokeratin 19 (CK19) staining. We observed that both the
number of metastatic foci, as well as the size of the metastatic
lesions were significantly reduced in control vs. anti-Gas6
treatedmice (Figures 1D,E, Supplementary Figures 1E–G). As a
consequence the overall metastatic burden was very significantly
reduced in the mice treated with anti-Gas6 blocking antibody
compared to control mice (Figure 1F). These data suggest that
blockade of Gas6 affects the metastatic cascade at different
stages, affecting the metastatic spreading and/or initial seeding
as well as the metastatic outgrowth of disseminated pancreatic
cancer cells.
Tumor Associated Macrophages and
Fibroblasts Are the Main Sources of Gas6
in Pancreatic Cancer
Gas6 is a multifunctional protein that is secreted by different cell
types. Gas6 has been shown to be produced by macrophages in
pre-malignant lesions of a mammary tumor model (29) and in
xenograft and orthotopic models of colon and pancreatic
cancer (11). Gas6 can also be produced by tumor cells
(30) and fibroblasts (31). To determine which cell types
produce Gas6 in pancreatic tumors, tumors were harvested at
day 23, and tumor cells (CD45–/zsGreen+), non-immune
stromal cells (CD45–/zsGreen–), M1-like macrophages
(CD45+/F4/80+/CD206–) and M2-like macrophages
(CD45+/F4/80+/CD206+) were isolated by flow cytometry
(Figure 2A, Supplementary Figure 2A) and analyzed for
the expression of gas6 (Figures 2A,B). We found that both
F4/80+/CD206+ (M2-like macrophages) and αSMA+ stromal
cells (Supplementary Figure 2B) are the main sources of
Gas6 in pancreatic tumors (Figure 2B). Ex-vivo, bone-marrow
derived macrophages and pancreatic fibroblasts also produce
Gas6 (Figures 2B,C). In agreement with these findings, we
observed that tumor areas with activated Axl receptor were
often surrounded by TAMs and CAFs (Figure 2D). Analysis
of Axl expression and activation in pancreatic cancer patient
samples has been correlated with a poor prognosis (21, 22)
and Axl activation in cancer cells has been shown to support
EMT, cell proliferation, metastasis and drug resistance (5).
While these studies have mainly focused on analyzing the
expression and function of Axl on the cancer cells, Axl is also
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FIGURE 1 | Pharmacological blockade of Gas6 inhibits pancreatic cancer metastasis. (A) KPCluc/zsGreen (zsGreen) -derived pancreatic tumor cells (FC1242luc/zsGreen )
were orthotopically implanted into the pancreas of syngeneic C57BL/6 recipient mice, and mice were treated, starting at day 14 after tumor implantation, twice a
(Continued)
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FIGURE 1 | week i.p., with either isotype control IgG antibody or Gas6 blocking antibody (2 mg/kg). Primary pancreatic tumors, livers, lungs, and mesenteric lymph
nodes were harvested at day 30. (B) Tumor weights (n = 11 mice for control IgG treatment group; n = 12 mice for anti-Gas6 treatment groups). (C) Representative
IVIS images of metastatic lungs from control IgG and anti-Gas6 treated mice. (D) Representative images of H&E staining of metastatic lungs from control IgG and
anti-Gas6 treated mice. Scale bar 50µm. (E) Quantification of number of lung metastatic foci per 100 mm2 in mice treated with control IgG or anti-Gas6 antibody
identified by H&E. *p ≤ 0.05, using unpaired student T-test, error bars represent SEM (n = 7). (F) Average size of pulmonary metastatic lesions in mice treated with
control IgG or anti-Gas6 antibody identified by H&E. *p ≤ 0.05, using unpaired student T-test, error bars represent SEM (n = 7). (G) Quantification of total metastatic
burden in mice treated with control IgG or anti-Gas6 antibody identified by H&E. **p ≤ 0.01, using unpaired student T-test, error bars represent SEM (n = 7).
expressed in immune cells, endothelial cells and stromal cells
and regulates innate immunity (3, 4), angiogenesis (32–34),
and fibrosis (31). In agreement with this multi-functional role
for Axl, we found that Axl is activated in both the tumor and
the stromal/immune compartment in biopsies from pancreatic
cancer patients (Figures 3A,B).
Gas6 Blockade Alters EMT of Pancreatic
Cancer Cells but Does Not Affect
Angiogenesis or Collagen Deposition in
Pancreatic Tumors
Previous studies have shown that Gas6-Axl signaling promotes
tumor cells’ EMT (35, 36). To determine whether the reduced
metastasis observed when we block Gas6 was caused by an
effect on tumor cell EMT, we evaluated the expression of
EMT markers and transcription factors on tumor cells from
pancreatic tumors treated with isotype control antibody or Gas6
blocking antibody. Tumor cells isolated from pancreatic tumors
were analyzed for the expression of the EMT transcription
factors Snail 1, Snail 2, Twist 1, Twist 2, Zeb 1, and Zeb 2
(Figure 4A), the epithelial markers E-cadherin, b-catenin, and
Epcam and the mesenchymal markers Vimentin and N-cadherin
(Figure 4B). We found that blocking of Gas6 significantly
decreased the expression of the EMT transcription factors Snail
1, Snail 2, and Zeb 2, while twist 1 and Zeb 1 levels remained
unchanged and twist 2 was not expressed in pancreatic cancer
cells (Figure 4A). In agreement with this observation, Gas6
blockade also decreased the expression of the mesenchymal
marker Vimentin, while N-cadherin levels were very low and
remained unchanged. E-cadherin and B-catenin levels were
also decreased though upon anti-Gas6 treatment, suggesting
that Gas6 signaling partially regulates cancer cell plasticity, a
phenomenon previously described in cancer (37, 38). Kirane
et al. (23) previously showed that blocking Gas6 signaling with
warfarin decreases vimentin expression in a xenograft model of
pancreatic cancer.
To further investigate the effect of anti-Gas6 on vimentin
expression in pancreatic cancer cells in our in vivo tumor model,
we analyzed vimentin protein expression in pancreatic tumor
tissues from control and anti-Gas6 treated mice (Figures 4C,D).
We found that blockade of Gas6 partially reduces vimentin
protein expression in cancer cells, although this decrease was not
statistically significant.
Pancreatic tumors are usually poorly vascularized but since
Gas6 signaling can support endothelial cells proliferation
and vascularization (33, 39, 40) we next evaluated whether
anti-Gas6 therapy could affect angiogenesis in pancreatic
tumors. Pancreatic tumor tissues from control and anti-Gas6
treated mice were stained with the endothelial marker CD31.
Whole tumor tissues were scanned and quantified for CD31
expression which remained unchanged in both treatment groups
(Supplementary Figures 3A,B). Fourcot et al. (31) showed, in
a liver fibrosis model, that Gas6 is secreted by macrophages
and fibroblasts and that Gas6 deficiency decreases TGFb
and collagen I production by hepatic fibroblasts. Gas6 also
stimulates the proliferation of cardiac fibroblasts (41). Since
fibrosis and collagen deposition have been suggested to re-
strain the metastatic spreading of pancreatic cancer cells
(42–45), we next investigated whether Gas6 blockade could
affect fibroblasts and collagen deposition in pancreatic tumors.
Pancreatic tumor tissues from control and anti-Gas6 treated
mice were stained with picrosirius red to assess collagen
deposition (Supplementary Figures 3C,D) and for αSMA+
cells (Supplementary Figures 3E,F). Whole tumor tissues were
scanned and quantified for collagen deposition (Sirius red
positive areas) and αSMA+ cells. We observed a slight increase
in collagen deposition in tumors from mice treated with
anti-Gas6 antibody compared to control but this increase
was not statistically significant (Supplementary Figures 3C,D).
αSMA levels remained the same in both treatment groups
(Supplementary Figures 3E,F). These findings suggest that the
anti-metastatic effect of Gas6 blockade in pancreatic cancer is not
due to changes in angiogenesis or fibrosis.
Gas6 Blockade Does Not Affect Myeloid
Cells or T Cells Populations at the Primary
Tumor Site, in Peripheral Blood or at the
Metastatic Site
TAM receptors are also expressed by immune cells and
regulate myeloid cell and T-cell functions (3, 46). Thus,
next, with the aim to understand the systemic effect of Gas6
blockade in myeloid cells and T cells in pancreatic cancer,
we evaluated the number and activation status of myeloid
cells and T cells in pancreatic tumors, blood and metastatic
tissues using mass and flow cytometry. Mass cytometry
analysis of myeloid (CD11b+) cells, neutrophils/MDSCs
(CD11b+/Ly6G+), monocytes (CD11b+/Ly6C+), macrophages
(CD11b+/F4/80+), MHC-II+, CD206+, and PD-L1+
macrophages (Figure 5A) and T cells (CD3+), helper T-cells
(CD3+/ CD4+), regulatory T cells (CD3+/CD4+/CD25+),
cytotoxic T cells (CD3+/CD8+), activated/exhausted cytotoxic
T cells (CD8+/CD69+; CD8+/PD-1+) (Figure 5B) from
pancreatic tumors from control vs. anti-Gas6 treated mice
did not show any significant differences (Figures 5A,B,
Frontiers in Immunology | www.frontiersin.org 4 February 2020 | Volume 11 | Article 297
Ireland et al. Gas6 Blockade Prevents Cancer Metastasis
FIGURE 2 | TAMs and CAFs are the main sources of Gas6 in pancreatic tumors. (A) KPCluc/zsGreen (zsGreen) -derived tumor cells (FC1242luc/zsGreen ) were
orthotopically implanted into the pancreas of syngeneic recipient (C57/BL6) mice. Tumors were harvested and digested at day 23 after implantation and tumor cells,
non-immune stromal cells, M1-like and M2-like macrophages were sorted by flow cytometry. Gas6 mRNA levels were quantified in CD45–/zsGreen+ tumor cells,
CD45–/zsGreen– non-immune stromal cells, CD45+/F4/80+/CD206– M1-like macrophages and CD45+/F4/80+/CD206+ M2-like macrophages sorted by flow
cytometry from murine pancreatic tumors. Values shown are the mean and SD (n = 3). (B) Quantification of Gas6 mRNA expression levels in ex vivo mouse primary
isolated macrophages and pancreatic fibroblasts from naïve mice. Values shown are the mean and SD (n = 3). (C) Immunoblotting analysis of Gas6 secreted protein
present in mouse macrophage conditioned media (MCM) and pancreatic fibroblast conditioned media (FCM). (D) Images show phospho-Axl, αSMA (fibroblast marker)
and CD68 (pan-macrophage marker) staining in naïve mouse pancreas and in serial sections of mouse PDA tissues. Scale bar = 50µm.
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FIGURE 3 | AXL receptor is activated in both the tumor and stromal compartment in biopsies from PDA patients. (A) Immunofluorescent staining of human PDA
biopsies with CK11 (tumor cell marker, in green), phospho-Axl receptor (in red), and nuclei (in blue). Scale bar, 50µm. Yellow arrow indicates presence of
phosphorylated Axl in the stromal compartment. White arrow indicates presence of phosphorylated Axl in the tumor cells. (B) Serial sections of biopsies from human
PDA samples immunohistochemically stained for phospho-Axl, CD163 (macrophages) and αSMA (fibroblasts). Cancer cells are indicated by a purple asterisk and
tumor stroma is indicated by a pink asterisk. Scale bars, 50 and 100µm.
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FIGURE 4 | Gas6 blockade in pancreatic tumors partially affects EMT of tumor cells. (A) Quantification of the expression levels of the EMT transcription factors: Snail
1, Snail 2, Twist 1, Twist 2, Zeb 1, and Zeb 2 in tumor cells (zsGreen+) isolated by flow cytometry from mouse PDA tumors. Values shown are the mean and SD
(n = 3). (B) Quantification of the expression levels of the epithelial markers: E-cadherin, b-catenin, EpCAM, and the mesenchymal markers vimentin and N-cadherin in
tumor cells FACS sorted from mouse PDA tumors. Values shown are the mean and SD (n = 3). *p ≤ 0.05, using unpaired student T-test; **p ≤ 0.01, using unpaired
student T-test; ***p ≤ 0.005, using unpaired student T-test. (C) Representative immunofluorescent images of vimentin staining at the periphery of mouse pancreatic
tumors treated with control IgG or anti-Gas6 antibody. The dashed lines highlight the areas quantified in the tumor tissues. (D) Quantification of vimentin protein
expression levels in pancreatic cancer cells. Data are displayed as mean and SEM and represent 5 images per mouse, with 7 animals per treatment group. n.s. no
statistically significant differences, using unpaired student T-test.
Supplementary Figures 4A,B). Similarly, myeloid cell and T
cell numbers in blood (Supplementary Figures 5A,B) and
metastatic lungs from mice treated with control or anti-Gas6
antibody remained the same (Supplementary Figures 6A,B).
Gas6 Blockade Restores NK Cell Activation
and Infiltration in Metastatic Lesions
TAM signaling is involved in the development of natural
killer (NK) cells (47). In an elegant study, Paolino et al.
(9) demonstrated that TAM receptor inhibition activates NK
cells cytotoxic function and thereby decreases metastasis in
mouse models of breast cancer and melanoma. Thus, we next
hypothesized that the anti-metastatic effect of Gas6 blockade we
observe in our pancreatic cancer model could be due to a re-
activation of NK cells. To test this hypothesis we evaluated NK
cells in primary pancreatic tumors, tumor draining lymph nodes,
and metastatic lesions of mice treated with control IgG or anti-
Gas6 antibody. NK cells were almost absent in all primary tumors
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FIGURE 5 | Gas6 blockade does not affect the composition or activation status of myeloid cells and T cells in pancreatic tumors. (A) Mass cytometry quantification of
CD11b + myeloid cells, Ly6C high/Ly6C low monocytes/MDSCs, Ly6G high/Ly6C low neutrophils/MDSCs, F4/80+ macrophages, MHCII+ macrophages,
(Continued)
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FIGURE 5 | CD206+ macrophages, and PD-L1+ macrophages in mouse pancreatic tumors treated with control IgG (n = 3) or anti-Gas6 neutralizing antibody (n =
4). Values shown are mean and SEM. n.s. no statistically significant differences, using unpaired student T-test. (B) Mass cytometry quantification of CD3+ T cells,
CD4+ T cells, CD4+/CD25+ regulatory T cells (Tregs), CD8+ T cells, CD69+/CD8+ T cells and PD-1+/CD8+ T cells in mouse pancreatic tumors treated with
control IgG (n = 3) or anti-Gas6 neutralizing antibody (n = 4). Values shown are mean and SEM. n.s. no statistically significant differences, using unpaired student
T-test. Graphs were generated with ViSNE data using Cytobank software.
from both anti-Gas6 and control treated mice (except for one
anti-Gas6 treated pancreatic tumor, Supplementary Figure 7).
However, the number of NKp46+ NK cells in lung metastatic
lesions was significantly higher in mice treated with anti-Gas6
antibody compared to control treated mice (Figures 6A,B).
The number of NK cells, and in particular the number of
proliferating NK cells, was also increased in tumor draining
lymph nodes from anti-Gas6 treated mice compared to control
treated mice (Figures 6C,D).
To further investigate the effect of inhibiting Gas6-Axl
signaling in pancreatic cancer progression and metastasis, we
performed another in vivo experiment, using our syngeneic
orthotopic KPC model (described in Figure 1) using warfarin
(instead of a neutralizing anti-Gas6 antibody). Warfarin is a
vitamin K antagonist that inhibits the vitamin k dependent γ-
carboxylation of Gas6 and prevents it from activating TAM
receptors (23, 48). Warfarin is currently being tested in
pancreatic cancer patients (NCT03536208). Similar to what
we observed with the anti-Gas6 treatment, warfarin reduced
pancreatic cancer metastasis to the lungs (Figures 7C,D,
Supplementary Figures 8A–C) and increased the number and
activation of NK cells in lungs (Figures 7E,F) and mesenteric
lymph nodes (Figures 7G,H), as shown by the increase in
NKp46+ and granzyme B expression. Warfarin treatment
also decreased vimentin expression in pancreatic cancer cells,
suggesting that warfarin also acts on the cancer cells altering their
plasticity (Supplementary Figures 8D,E).
DISCUSSION
The data presented in this study describe a dual anti-tumor
effect of Gas6 blockade in pancreatic tumors, shedding light on
the anti-cancer mechanism of action of inhibitors of the Gas6-
Axl pathway and supporting the rationale for using anti-Gas6
therapy in pancreatic cancer patients. In these studies we show
that blockade of Gas6 in pancreatic tumors, with either an anti-
Gas6 neutralizing antibody or with warfarin, acts simultaneously
on both the tumor cells, altering their epithelial-mesenchymal
phenotype, as well as on NK cells, promoting their activation and
recruitment to the metastatic site (Figures 6, 7). These findings
suggest that anti-Gas6 therapy decreases pancreatic cancer
metastasis by not only affecting cancer cells’ plasticity but also
by activating NK cells and supporting their tumoricidal function.
So far many studies have focused on the cancer-cell
autonomous role of Gas6 and based on their effect on tumor
cell proliferation and plasticity several inhibitors of the Gas6-Axl
pathways, including warfarin (clinical trial ID: NCT03536208)
are currently being tested in pancreatic cancer patients.
Our studies show that inhibition of Gas6 signaling in
pancreatic cancer not only affects the tumor cells but notably
affects the NK cells (Figure 8). Our findings suggest that the
activation status of NK cells should also be assessed in cancer
patients and could be used as a biomarker to monitor response
to anti-Gas6/Axl therapies.
Gas6/Axl signaling is a negative regulator of the immune
system and inhibition of the Gas6-Axl signaling leads to
autoimmunity (4). While the function of Gas6-Axl signaling on
tumor cell proliferation, EMT, migration and drug resistance has
been extensively studied (5), only a few studies have investigated
the role of Gas6/Axl signaling in the immune system in the
context of cancer (7, 9, 24). Guo et al. (7) found that the
Axl inhibitor R428 inhibited tumor growth of subcutaneously
implanted murine 4T1 breast cancer cells and intra-peritoneally
implanted murine ID8 ovarian cancer cells by activating CD4+
and CD8+ T cells. Inspired by this study, we investigated
whether, in our pancreatic cancer model, Gas6 blockade supports
the activation of T cells. Unlike Guo et al. (7) we did not
observe any statistically significant difference in CD4+ or CD8+
T cells in pancreatic tumors, blood or metastatic tissues, in
control vs. anti-Gas6 treated mice. Ludwig et al. (24) found that
treating mouse pancreatic tumors with the Axl inhibitor BGB324
decreased the number of tumor associated macrophages (TAMs)
in some but not all tumor models. In our study, blocking Gas6
did not significantly affect TAMs, other myeloid cell populations
or T cells in primary tumors, blood or metastatic organs. These
different results observed in these studies may be explained by the
differences in the tumormodels used (breast cancer vs. pancreatic
cancer; xenograft vs. syngeneic models) and the differences in
the therapies used (inhibition of AXL receptor vs. inhibition
of Gas6 ligand which binds all TAM receptors). In another
study, Paolino et al. (9) showed that TAM receptor inhibition
activates NK cells in mouse tumor models of melanoma and
breast cancer leading to decreased tumor growth. In agreement
with these findings, we found that blocking Gas6 in mice bearing
pancreatic tumors, increases NK cell number and activation in
tumor draining lymph nodes and lungs, and decreases pancreatic
cancer metastasis.
Inhibition of the Gas6-Axl pathway has been shown to reverse
EMT, tumor migration and intra-tumoral micro-vessel density
in pancreatic cancer (23). In agreement with these findings, we
found that inhibition of Gas6 signaling decreases the expression
of the EMT transcription factors Snail 1, Snail 2, Zeb2, and
vimentin expression in pancreatic cancer cells. E-cadherin and
b-catenin levels were also decreased upon anti-Gas6 treatment
suggesting that blockade of Gas6 signaling leads to a partial
MET or hybrid E/M phenotype. Partial EMT is a phenomenon
often observed in cancer, where cancer cells that originate
from epithelial cells exhibit both mesenchymal and epithelial
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FIGURE 6 | Gas6 blockade increases NK cell numbers in metastatic lungs and in tumor draining lymph nodes. (A) Immunohistochemical staining of NK cells in
metastatic lungs from pancreatic tumor bearing mice treated with control IgG or anti-Gas6 antibody. Lesions indicated by dashed line and NK cells by red asterisk.
Scale bar, 50µm. (B) Quantification of NK cells in metastatic lung tissues from control IgG and anti-Gas6 treated mice. Values shown are the mean and SEM (n = 6
mice in IgG treatment group, n = 7 mice in anti-Gas6 treatment group). **p ≤ 0.01, using unpaired student T-test. (C) Immunofluorescent staining of NK cells in
mesenteric lymph nodes from pancreatic tumor bearing mice treated with control IgG or anti-Gas6 antibody. NK marker NKp46 is shown in red, Ki67 is shown in
green and nuclei were stained with DAPI (in blue). Scale bar, 50µm. (D) Quantification of NK cells in tumor draining lymph nodes from control IgG and anti-Gas6
treated mice. Values shown are the mean and SEM (n = 6 mice IgG treatment group and n = 7 mice anti-Gas6 treatment group, 3–6 fields/ mouse tissue were
quantified). *p ≤ 0.05, using unpaired student T-test.
characteristics. The ability of cancer cells to undergo partial EMT,
rather than complete EMT and to maintain the expression of
both E-cadherin and vimentin poses a higher metastatic risk (37,
44). Pancreatic tumors are usually hypo-vascularized compared
to a normal pancreas and anti-angiogenic therapies have not
been successful in pancreatic cancer (49). Similar to the human
disease, in our pancreatic mouse tumor model, tumors are
poorly vascularized and blocking Gas6 did not show any further
decrease in tumor vascularization. Loges et al. (11) previously
showed that tumor associated macrophages (TAMs) produce
Gas6 in various mouse tumor models. In our study we found
that both TAMs and CAFs are the main sources of Gas6 in
pancreatic tumors. These findings suggest that the abundance
of TAMs and CAFs in pancreatic cancer patients could be
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FIGURE 7 | Warfarin decreases pancreatic cancer metastasis and increase NK cell numbers and activation in lymph nodes and at the metastatic site.
(A) KPCluc/zsGreen (zsGreen) -derived pancreatic tumor cells (FC1242luc/zsGreen ) were orthotopically implanted into the pancreas of syngeneic C57BL/6 recipient mice.
At day 14 the mice were treated with either control drinking water or warfarin sodium in drinking water (0.5 mg/L). Warfarin water was replenished every 3–4 days.
Primary tumors, livers, lungs and lymph nodes were harvested at day 29/30. (B) Tumor weights from control (n = 7) or warfarin (n = 6) treated mice. (C)
Immunohistochemical staining of CK19+ in mice with lung metastases. (D) Quantification of the total area of lung metastasis per mouse as a percentage of the total
lung area for control (n = 4) or warfarin (n = 3) treated mice. *p ≤ 0.05 using unpaired student T-test. Values shown are mean and SEM. (E) Immunohistochemical
staining of NKp46+ NK cells in the lungs from pancreatic tumor bearing mice. (F) Quantification of the number of NKp46+ NK cells per cm2 in the lungs of control (n
= 7) or warfarin (n = 6) treated mice. (G) Immunoflourescence staining of NK cells in the mesenteric lymph nodes from pancreatic tumor bearing mice. The NKp46
marker is shown in red, granzyme B is shown in green and the nuclei were stained with DAPI (in blue). Scale bar 50 µm. (H) Quantification of the number of NKp46+
and granzyme b+ cells in tumor draining lymph nodes for control (n = 7) and warfarin (n = 6) treated mice. Values shown are the mean and SEM and 3-10
fields/mouse tissue were quantified.
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FIGURE 8 | Schematics depicting the multifunctional role of stroma-derived Gas6 in pancreatic cancer. In vivo blockade of Gas6 signaling with a neutralizing
anti-Gas6 antibody or warfarin, partially reverses tumor cells EMT and activates NK cells, leading to a decrease in pancreatic cancer metastasis.
used to determine which patients would benefit the most from
anti-Gas6 therapy.
In conclusion, our studies suggest that in pancreatic
cancer, Gas6 is secreted by both TAMs and CAFs and
blockade of Gas6 signaling has a dual anti-metastatic effect
by acting on both the tumor cells and the NK cells.
Thus, inactivation of Gas6 signaling can promote anti-tumor
immunity, via NK cell activation, in pancreatic tumors.
Since this Gas6-dependent immune regulation of NK cells is
also conserved in humans, anti-Gas6-Axl therapies are likely
to promote anti-tumor immunity, via NK cell activation,
in pancreatic cancer patients. This study provides further
mechanistic insights into the mode of action of anti-Gas6
therapies and suggests the use of NK cells as an additional
biomarker for response to anti-Gas6 therapies in pancreatic
cancer patients.
MATERIALS AND METHODS
Generation of Primary KPC-Derived
Pancreatic Cancer Cells
The murine pancreatic cancer cells KPC FC1242 were generated
in the Tuveson lab (Cold Spring Harbor Laboratory, New
York, USA) isolated from PDA tumor tissues obtained from
LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre mice of a pure
C57BL/6 background as described previously with minor
modifications (50).
Generation of Primary Macrophages,
Primary Pancreatic Fibroblasts,
Macrophage (MCM, and Fibroblasts (FCM)
Conditioned Media
Primary murine macrophages were generated by flushing
the bone marrow from the femur and tibia of 6–8 week-
old C57BL/6 mice followed by incubation for 5 days in
DMEM containing 10% FBS and 10 ng/mL murine M-CSF
(Peprotech). Primary pancreatic stellate cells were isolated
from the pancreas of C57BL/6 mice by density gradient
centrifugation, and were cultured on uncoated plastic dishes
in IMDM with 10% FBS and 4mM L-glutamine. Under
these culture conditions pancreatic stellate cells activated
into myofibroblasts.
To generate macrophage and fibroblast conditioned media,
cells were cultured in serum free media for 24–36 h, supernatant
was harvested, filtered with 0.45µm filter, concentrated using
StrataClean Resin (Agilent Technologies) and immunoblotted
for Gas6 (R&D Systems, AF885).
Immunoblotting
FC1242 cells were plated in DMEM media with 10% FBS for
24 h, harvested and lysed in RIPA buffer (150mM NaCl, 10mM
Tris-HCl pH 7.2, 0.1% SDS, 1% Triton X-100, 5mM EDTA)
supplemented with a complete protease inhibitor mixture
(SIGMA), a phosphatase inhibitor cocktail (Invitrogen),
1mM PMSF and 0.2mM Na3VO4. Immunoblotting
analyses was performed using phospho-Axl antibody (R&D
systems, AF2228).
Syngeneic Orthotopic Pancreatic Cancer
Model
1 × 106 primary KPCluc/zsGreen cells (FC1242luc/zsGreen) isolated
from a pure C57Bl/6 background were implanted into the
pancreas of immune-competent syngeneic C57Bl/6 six- to 8
week-old female mice, and tumors were established for 2 weeks
before beginning treatment. Mice were administered i.p. with
Gas6 neutralizing antibody (R&D systems, AB885) (2 mg/kg), or
IgG isotype control antibody, every 3–4 days or warfarin sodium
in drinking water (0.5 mg/L) which was replenished every 3–4
days, for 15 days before harvest.
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Analysis and Quantification of Immune
Cells in Pancreatic Tumors by Mass
Cytometry
Pancreatic tumors were resected from the mice and mechanically
and enzymatically digested in Hanks Balanced Salt Solution
(HBSS) with 1mg/mL Collagenase P (Roche) Cell suspensions
were centrifuged for 5min at 1,500 rpm, resuspended in HBSS
and filtered through a 500µm polypropylene mesh (Spectrum
Laboratories). Cells were resuspended in 1mL 0.05%Trypsin
and incubated at 37
◦
C for 5min. Cells were filtered through
a 70µm cell strainer and resuspended in Maxpar cell staining
buffer (Fluidigm). The samples were centrifuged for 5min at
450 x g and supernatant removed. The cells were subsequently
stained with Cell-ID 195-Cisplatin (Fluidigm) viability marker
diluted 1:40 in Maxpar PBS (Fluidigm) for 5min. Cells were
centrifuged at 450 x g for 5min and washed twice in Maxpar
cell staining buffer. Samples were blocked for 10min on ice
with 1:100 diluted FC Block (BD Pharmingen, Clone 2.4G2)
and metal-conjugated antibody cocktail added and incubated
for 30min at 4
◦
C. Antibodies were used at the concentrations
recommended by manufacturers. Cells were washed twice in
cell staining buffer and stained with 125µM 191-Intercalator-
Ir (Fluidigm) diluted in 1:2,000 Maxpar fix and perm buffer
(Fluidigm) overnight at 4
◦
C. The cells were washed twice
in Maxpar cell staining buffer and centrifuged at 800 x g
for 5min. A post-fix was performed by incubating the cells
in 1.6% PFA for 30min at RT. Cells were washed twice
in 18 distilled water (Fluidigm), mixed 1:10 with EQTM
Four Element Calibration Beads (Fluidigm) and acquired
on the Helios CyTOF system (Fluidigm). Samples were
acquired at a rate of around 200 cells/s. All generated FCS
files were normalized and beads removed (51). All analysis
was performed in Cytobank: Manual gating was used to
remove dead cells (195Pt+) and debris and to identify single
cells (191 Ir+).
viSNE analysis was performed on the data utilizing
t-stochastic neighbor embedding (t-SNE) mapping based
on high dimensional relationships. CD45+ population selected
by manual gating was used as the starting cell population and
using proportional sampling viSNE unsupervised clustering
was performed. Manual gating was then performed on the
viSNE map created to determine cell population percentages.
Spanning-tree Progression Analysis of Density-normalized
Events (SPADE) analysis was performed in Cytobank using
manually gated CD45+ cells, 200 target number of nodes and
10% down sampled events, to equalize the density in different
parts of the cloud. In Cytobank SPADE analysis edge number
between nodes indicates levels of similarity, with more steps
indicating less similarity across channels used to create the
tree. Node localization and edge length cannot be used to
infer similarity in this analysis. Event number is indicated
by both color scale and node size (which is proportional to
the number of cells present in each cluster). Gating of cell
populations was performed to identify major cell populations
and percentages.
FACS Sorting and Analysis of Blood and
Lungs by Flow Cytometry
Single cell suspensions from murine primary pancreatic tumors
and pulmonary metastasis were prepared by mechanical
and enzymatic disruption and tumor cells, tumor associated
macrophages and stromal cells were analyzed and sorted using
flow cytometry (FACS ARIA II, BD Bioscience). Samples were
digested as outlined above, the cells were then filtered through
a 70µm cell strainer and resuspended in PBS + 1% BSA,
blocked for 10min on ice with FC Block (BD Pharmingen,
Clone 2.4G2) and stained with Sytox R© blue viability marker (Life
Technologies) and conjugated antibodies anti-CD45-PE/Cy7
(Biolegend, clone 30-F11) and anti-F4/80-APC (Biolegend,
clone BM8).
Blood was collected from mice via tail vein bleed in EDTA-
tubes. Red blood cell lysis was performed and resulting leukocytes
were resuspended in PBS + 1% BSA and blocked for 10min on
ice with FC block and stained with Sytox R© blue viability marker
and conjugated antibodies anti-CD45-APC/Cy7 (Biolegend,
103115), anti-CD11b-APC (Biolegend, 101212), anti-Ly6G-
PerCP-Cy5.5 (Biolegend, 127616), anti-Ly6C-PE (Biolegend,
128008), anti-CD3-PE-Cy7 (Biolegend, 100320), anti-CD4-PE
(Biolegend, 100408), and anti-CD8-PerCP-Cy5.5 (Biolegend,
100734). Cell analysis was performed using FACS Canto II.
Gene Expression
Total RNA was isolated from FACS sorted tumor cells, tumor
associated macrophages and non-immune stromal cells from
primary pancreatic tumors as described in Qiagen Rneasy
protocol. Total RNA from the different cell populations was
extracted using a high salt lysis buffer (Guanidine thiocynate
5M, sodium citrate 2.5 uM, lauryl sarcosine 0.5% in H2O) to
improve RNA quality followed by purification using Qiagen
Rneasy protocol. cDNA was prepared from 1µg RNA/sample,
and qPCR was performed using gene specific QuantiTect Primer
Assay primers from Qiagen. Relative expression levels were
normalized to gapdh expression according to the formula <2∧–
(Ct gene of interest—Ct gapdh) (52).
Quantification of Metastasis
By IVIS Imaging
IVIS spectral imaging of bioluminescence was used for
orthotopically implanted tumor cells expressing firefly luciferase
using IVIS spectrum system (Caliper Life Sciences). Organs were
resected for ex vivo imaging coated in 100µL D-luciferin (Perkin
Elmer) for 1min and imaged for 2min at automated optimal
exposure. Analysis was performed on the Living Image software
(PerkinElmer) to calculate the relative bioluminescence signal
from photon per second mode normalized to imaging area (total
flux) as recommended by the manufacturer.
By H&E Staining
FFPE lungs were serially sectioned through the entire lung using
microtome at 4µm thickness. Sections were stained with H&E
and images were taken using a Zeiss Observer Z1 Microscope
(Zeiss) to identify metastatic foci. The number of foci were
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counted, and the total area of metastatic foci was measured using
Zen imaging software. Metastatic burden was calculated by the
following equations:
No. of foci per 100mm2: (Average no. foci per section/ average
tissue area per section (mm2) ∗100
Average metastatic lesion size (mm2): Average total area of
metastasis (mm2)/ average number of foci per section
Total metastatic burden: Sum of area of each foci of
each section.
By CK19 Staining
FFPE Lung tissue sections were also stained for cytokeratin 19
(CK19). The slides were scanned with an Aperio slide scanner




Deparaffinization and antigen retrieval was performed using
an automated DAKO PT-link. Paraffin-embedded pancreatic
tumors, lymph nodes, and lung metastasis tissues were immuno-
stained using the DAKO envision+ system-HRP.
Antibodies and Procedure Used for
Immunohistochemistry
All primary antibodies were incubated for 2 h at room
temperature: αSMA (Abcam, ab5694 used at 1:200 after
low pH antigen retrieval), CD31 (Cell signaling technology,
CST 77699 used at 1:100 after low pH antigen retrieval),
NKp46 (Biorbyt, orb13333 used at 1:200) and AF2225 (used
at 1:50 after low pH antigen retrieval), CK19 (ab53119 used
at 1:100 after low pH antigen retrieval), and CD68 (Abcam,
ab31630 used at 1:400 after low pH antigen retrieval).
Subsequently, samples were incubated with secondary
HRP-conjugated antibody (from DAKO envision kit) for
30min at room temperature. All antibodies were prepared
in antibody diluent from Dako envision kit. Staining was
developed using diamino-benzidine and counterstained
with hematoxylin.
Human paraffin-embedded PDA tissue sections were
incubated overnight at RT with the following primary antibodies:
phospho-Axl (R&D, AF2228, used 1:500 after high pH antigen
retrieval), CD163 (Abcam, ab74604 pre-diluted after low pH
antigen retrieval), αSMA (Abcam, ab5694 used 1:100 after low
pH antigen retrieval).
Antibodies and Procedure Used for
Immunofluorescence
After low pH antigen retrieval, lymph node tissue sections
derived from mice bearing pancreatic tumors were incubated
overnight at RT with the following primary antibodies:
NKp46 (R&D systems AF2225, used at 1:25), Ki67 (Abcam
ab15580, used at 1:1000), vimentin (Abcam ab92547, used at
1:400), and Granzyme B (ab4059, used at 1:600). Vimentin
expression was quantified on cancer cells located at the edge
of pancreatic tumors. Samples were washed with PBS and
incubated with donkey anti-goat 594 (Abcam ab150132) and
donkey anti-rabbit 488 (Abcam ab98473) secondary antibodies,
respectively, all used at 1:300 and DAPI at 1:600 for 2 h
at RT. Slides were washed with PBS, final quick wash
with distilled water and mounted using DAKO fluorescent
mounting media.
After low pH antigen retrieval, mouse tissue sections derived
from paraffin embedded pancreatic tumors were incubated with
vimentin (ab92547, used at 1:400) overnight at 4c. Goat anti-
rabbit 594 (ab150080) secondary was used at 1:300 and DAPI at
1:600 for 2 h at RT.
Human PDA frozen tissue sections were fixed with cold
acetone, permeabilized in 0.1% Triton, blocked in 8% goat
serum and incubated overnight at 4◦C with anti-phospho-
Axl (R&D, AF2228, diluted 1:200) CK11 (Cell signaling,
CST 4545, diluted 1:200), followed by fluorescently labeled
secondary antibodies goat anti mouse 488 (Abcam ab98637),
goat anti-rabbit 594 (Abcam ab98473) used at 1:300 for
2 h at RT slides were washed with PBS, final quick wash
with distilled water and mounted using DAKO fluorescent
mounting media.
Picrosirius Red Staining
FFPE PDA tumor sections were deparaffinized in two 5min
xylene washes and through decreasing alcohol washes of 100,
75, and 65% each 5min. The slides were washed for 5min
in distilled water and incubated in 0.2% phosphomolybdic
acid for 5min. After washing in PBS, were stained with
0.1% Sirius red F3B in saturated picric acid solution for
90min. After two rinses in acidified water the slides were
stained with fast green (0.01%) for 1min. The sections were
rinsed twice in acidified water were rapidly dehydrated using
three steps of 100% ethanol and two xylene incubations
of 30 s.
Statistical Methods
Statistical significance for in vitro assays and animal studies
was assessed using unpaired two-tailed Student t-test and the
GraphPad Prism 5 program. All error bars indicate SD for in vitro
studies and SEM for animal studies.
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